Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.


TSXV:ARCH - Post by User

Post by 2019champson Aug 07, 2021 12:22pm
110 Views
Post# 33668374

Long Covid

Long CovidFor majority of people Covid is a 2 week illness you deal with, and you usually go back to normal. For others, that's not the case. Some people feel lingering effects for several weeks, and months. Have a look at this article, and then look at publication on what LSALT does. https://www.news-medical.net/amp/news/20210607/Could-sustained-inflammation-following-mild-to-moderate-COVID-19-be-a-driver-of-long-COVID.aspx "IL-8 is produced by lung epithelium and by airway resident macrophages and promotes the migration of inflammatoryT cellsand neutrophils into the lung tissue, leading to alveolar damage. Its levels persist at high levels in LC, perhaps promoting long-term inflammation" What lsalt peptide does according to publications: "In the publication, DPEP-1 was identified for the first time as a major leukocyte (white blood cell) adhesion receptor on the lung, liver and kidneyendothelium. LSALT differs from typical anti-inflammatory drugs by targeting this novel adhesion receptor rather than targeting individual cytokines, of which there are over 30 currently known.
<< Previous
Bullboard Posts
Next >>